Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) - Episode 11

Determining Which DTC Patients May Benefit from Systemic Therapy

April 26, 2024

Lori J. Wirth, MD, Francis Worden, MD, Marcia S. Brose, MD, PhD, Daniel Bowles, MD, Hyunseok Kang, MD

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

EP. 1: Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

EP. 2: Exploring Incidence and Histology of Differentiated Thyroid Cancer

EP. 3: Determining Prognosis for Patients with Differentiated Thyroid Cancer

EP. 4: Predisposition for Patients Developing DTC: Age and Gender

EP. 5: The Role of Molecular Diagnostics in Real-World DTC Management

EP. 6: Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

EP. 7: The Importance of Thyroidectomy in DTC Patient Care

EP. 8: Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

EP. 9: Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

EP. 10: SELECT Trial & DECISION Trial Outcomes and Lessons Learned

Now Viewing

EP. 11: Determining Which DTC Patients May Benefit from Systemic Therapy